BEDFORD, Mass., June 15, 2015 /PRNewswire/
-- Hologic, Inc. (NASDAQ: HOLX) announced today that
award-winning actress and singer Kristin
Chenoweth will serve as spokesperson for a national campaign
to generate awareness of Hologic's Genius 3D Mammography exam, a
more accurate mammogram that has been clinically proven to reduce
callbacks by up to 40 percent and detect 41 percent more invasive
cancers than traditional 2D mammography alone.1,2
A Tony and Emmy award-winner who is currently starring on
Broadway in the critically-acclaimed musical On the Twentieth
Century, Chenoweth is the daughter of a two-time breast cancer
survivor and understands how critical it is that women take
advantage of the best screening options available.
"Every woman knows that early detection is crucial when it comes
to fighting breast cancer, but what so many don't realize is that
not all mammograms are the same," said Chenoweth. "That's why
I'm partnering with Hologic and urging women across the country to
demand that their hospitals or facilities offer the Genius 3D
Mammography exam. Women need to take advantage of this more
accurate* screening -- but that's only possible if they have
access to it."
The "Demand Genius" 3D campaign will kick off on June 19 with a satellite media tour in New York
City. The campaign website, DemandGenius3D.com, explains the
advanced technology behind the Genius 3D Mammography exam and
provides a ZIP code locator that identifies facilities offering
it. Women can go to DemandGenius3D.com to see if their
preferred facility offers a Genius 3D Mammography exam and make
their appointment. Through links on the site, visitors also
can contact facilities that do not offer the Genius 3D Mammography
exam to demand it. Additional campaign components taking
place in June include a charitable partnership with
BreastCancer.org and a blogger activation program.
"Hologic has long been committed to developing technologies that
improve women's health, and the Genius 3D Mammography exam is one
remarkable example of that commitment," said Pete Valenti, Hologic's Division President,
Breast and Skeletal Health Solutions. "We're thrilled that
Kristin shares our passion and is helping us educate women across
the country about how they can empower themselves to have access to
breast cancer screening that's more accurate than 2D mammography
alone."
The Genius 3D Mammography exam is only available on the Hologic
Selenia Dimensions system. Since 2011, over 8 million women
in the United States have been
screened using the Genius 3D Mammography exam.
About Hologic
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and
surgical products. The Company's core business units focus on
diagnostics, breast health, GYN surgical, and skeletal
health. With a unified suite of technologies and a robust
research and development program, Hologic is dedicated to The
Science of Sure. For more information on Hologic, visit
www.hologic.com.
Hologic, Genius, 3D Mammography, Selenia, Dimensions, The
Science of Sure and associated logos are trademarks and/or
registered trademarks of Hologic, Inc. and/or its subsidiaries in
the United States and/or other
countries.
Forward-Looking Statements
This news release contains forward-looking information that
involves risks and uncertainties, including statements about the
Company's plans, objectives, expectations and intentions, and
statements regarding the Company's commercial activities.
These forward-looking statements are based on assumptions made by
the Company as of this date and are subject to known and unknown
risks and uncertainties that could cause actual results to differ
materially from those anticipated. These risks include, but
are not limited to, the risk that the Company's sales and marketing
strategies may not increase demand for Genius 3D Mammography exams
or other products. These risks are not exhaustive.
Other factors that could adversely affect the Company's business
and prospects are described in the filings made by the Company with
the SEC. The Company expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
such statements presented here to reflect any change in
expectations or any change in events, conditions or circumstances
on which any such statements are based.
*Compared to 2D mammography
alone.
References: 1. Friedewald S, Rafferty E, Rose S, et al.
Breast cancer screening using tomosynthesis in combination with
digital mammography. JAMA. 2014;311(24):2499-2507. 2.
Rose S, Tidwell A, Bujnoch L, et al. Implementation of breast
tomosynthesis in a routine screening practice: an observational
study. AJR AM J Roentgenol. 2013;200(6):1401-1408.
Contact
Michael Watts
Vice President, Investor Relations and
Corporate Communications
(858) 410-8588
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/kristin-chenoweth-named-national-celebrity-spokesperson-for-hologics-demand-genius-3d-breast-cancer-screening-campaign-300099183.html
SOURCE Hologic, Inc.